Jupiter Endovascular
PrivateLast Round
Series B
Oct 7, 2025
Total Funding Raised
$61M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Jupiter Endovascular operates in Healthcare & Life Sciences and is based in Menlo Park, California. Its latest recorded funding round was a Series B round in October 2025.
Jupiter Endovascular is a medical technology company that develops catheter-based endovascular intervention systems using its proprietary Transforming Fixation (TFX) platform technology.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Jupiter Endovascular Comparables
Compare Jupiter Endovascular with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Endovascular Engineering, Inc. | 87% | |
| Inquis Medical | 80% | |
| Liquet Medical Inc. | 76% |
For institutional investors. Book with your work email.
Jupiter Endovascular Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 7, 2025 | ||||
| Seed | Aug 15, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Jupiter Endovascular Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Senvest Management | Series B |
| LB Investment | Series B |
| Sonder Capital | Seed, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 30% MoM, reaching 2.1K.
- Jul 20, 2026
Open roles increased to 48, 84% of headcount.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 29, 2026
Jupiter Endovascular, Inc. hires Dr. Toma as chief medical officer, bringing his extensive clinical and research experience in structural heart and interventional medicine to the company.
- hiresAug 13, 2026
Jupiter Endovascular, Inc. appoints interventional cardiologist Catalin Toma as chief medical officer on Aug 13th '26.
For institutional investors. Book with your work email.
Jupiter Endovascular Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Jupiter Endovascular's valuation, stock price, and market status.
Is Jupiter Endovascular a public or private company?
Jupiter Endovascular is a private company.
What is the current stock price of Jupiter Endovascular?
Jupiter Endovascular is a private company, so its shares have no public market price. Caplight tracks Jupiter Endovascular's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Jupiter Endovascular worth (valuation)?
Valuation information for Jupiter Endovascular is not publicly available.
Can I buy Jupiter Endovascular stock?
Jupiter Endovascular shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Jupiter Endovascular's last funding round?
Jupiter Endovascular's most recent funding round was Series B on October 7, 2025.
Who are the main investors in Jupiter Endovascular?
Key investors in Jupiter Endovascular include Sonder Capital.
Will Jupiter Endovascular IPO soon?
No public IPO plans have been announced for Jupiter Endovascular.
How can I track Jupiter Endovascular secondary market activity?
Caplight tracks bids, offers, and trades in Jupiter Endovascular's shares on secondary markets.